News

How High Can SAVA Stock Go Once the Controversy Clears?

  • Sometimes, it's hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ: SAVA ).
    09/30/2022

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

  • This is a highly speculative bet. There has been a constant litany of accusations of wrongdoing on the science.
    09/29/2022
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Cassava Sciences, Inc. (SAVA) can buy. Click on Rating Page for detail.

The price of Cassava Sciences, Inc. (SAVA) is 42.28 and it was updated on 2022-10-06 13:00:26.

Currently Cassava Sciences, Inc. (SAVA) is in undervalued.

News
    
News

Should you buy Cassava Sciences as the stock continue to soar

  • Retail interest in Cassava Sciences (NASDAQ:SAVA) remains far from over. The stock gained more than 6.7% on Wednesday, catapulting it to a 76% increase in value in a month.
    Wed, Sep. 28, 2022

Why Is Cassava Sciences (SAVA) Stock Heating Up Today?

  • Casava Sciences (NASDAQ: SAVA ) stock rose 5% overnight in sympathy with Biogen's (NASDAQ: BIIB ) successful clinical trial of an Alzheimer's drug called lecanemab. Lecanemab, developed with Eisai (OTCMKTS: ESALY ) of Japan, showed a decline in symptoms among 1,795 patients with early Alzheimer's, a brain disease impacting nearly one-third of Americans ages 85 and older.
    Wed, Sep. 28, 2022

5 Investors Betting Big on Cassava (SAVA) Stock

  • Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day's gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on Cassava.
    Fri, Sep. 23, 2022

Cassava: High Risk Speculative Play With Enormous Potential

  • Initiation of a phase 3 program open-label extension study using Simufilam for patients with Alzheimer's Disease is expected in 2nd half of 2022. An ongoing long-term open label study, initiated in March of 2020 is ongoing; Dosing completion is expected Q4 of 2022 and results from it are expected before end of 2022.
    Thu, Sep. 22, 2022

The Huge Reason Cassava Sciences (SAVA) Stock Is Rocketing Higher

  • Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That's because the Securities and Exchange Commission (SEC) has closed its case on Cassava following the initiation of an investigation last November.
    Thu, Sep. 22, 2022
SEC Filings
SEC Filings

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 07/29/2022

Cassava Sciences, Inc. (SAVA) - S-8

  • SEC Filings
  • 06/10/2022

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 02/11/2021

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 11/16/2020

Cassava Sciences, Inc. (SAVA) - FWP

  • SEC Filings
  • 11/13/2020

Cassava Sciences, Inc. (SAVA) - 424B5

  • SEC Filings
  • 11/12/2020

Cassava Sciences, Inc. (SAVA) - 424B2

  • SEC Filings
  • 05/05/2020

Cassava Sciences, Inc. (SAVA) - S-3/A

  • SEC Filings
  • 04/09/2020

Cassava Sciences, Inc. (SAVA) - S-3

  • SEC Filings
  • 03/27/2020
Press Releases
StockPrice Release

Cassava update

  • 10/23/2021

Cassava update

  • 10/16/2021
More Headlines
News

Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data

  • The SEC reportedly cleared an investigation into Cassava Sciences, leading SAVA stock to hit a seven-month high Thursday. The post Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data appeared first on Investor's Business Daily.
  • 09/22/2022

The SEC Has Officially Cleared Cassava Sciences

  • Cassava Sciences increased by over 10% intraday on positive SEC news. Cassava Sciences is up 26% in the last month while the market is down 7%.
  • 09/22/2022

What Is Going on With Cassava (SAVA) Stock Today?

  • Cassava Sciences (NASDAQ: SAVA ) stock rose nearly 30% on Sept. 20 as speculators bet on the company's efforts against Alzheimer's Disease.
  • 09/21/2022

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

  • AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York.
  • 09/08/2022

Cassava Sciences Looks As Good Of A Purchase As Ever

  • Multiple insiders have purchased shares on the open market in the last month. The company has now released positive 100 patient 12-month data.
  • 09/03/2022

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock

  • Cassava Sciences (NASDAQ: SAVA ) rose 9% overnight on reports director Richard Barry has invested $860,000 in the company's stock. The stock was due to open Aug. 26 at almost $30 per share, a market capitalization of almost $1.2 billion.
  • 08/26/2022

These Are The Ten Best And Worst Performing Small-Cap Stocks In July 2022

  • The small-cap Russell 2000 gained over 10% in July, compared to a jump of 9.1% for the S&P 500.
  • 08/22/2022

Cassava Sciences, Blue Apron, and Revlon Stocks Exploded Out of the Gate Wednesday Morning

  • These vastly different companies have one thing in common.
  • 08/17/2022

Why Is Cassava Sciences (SAVA) Stock Up 20% Today?

  • Cassava Sciences (NASDAQ: SAVA ) rose 20% in overnight trading after board member Sanford Robertson bought 100,000 shares. Chief financial officer Eric Schoen also bought shares.
  • 08/17/2022

Stocks to watch: Apple, Digital World Acquistion Corp, Cassava Science, Canoo

  • Yahoo Finance Live host Seana Smith breaks down the action surrounding trending stocks in after-hours trading, including how the Trump-tied SPAC is filing to delay earnings.
  • 08/16/2022

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

  • After at least one year, 50 participants on simufilam experienced a 3.2 point improvement in ADAS-Cog scores whereas another group of 50 participants saw a .2 decline (on average). Acetylcholinesterase inhibitors produce a result between these two points in most individuals after one year.
  • 08/11/2022

10 Stocks to Sell Before They Die

  • This article is excerpted from Tom Yeung's Profit & Protection newsletter dated July 28, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
  • 07/29/2022

Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe

  • Cassava Biosciences (NASDAQ: SAVA ) stock is tumbling 30% in pre-market trading after Reuters reported today that the Justice Department has launched a criminal probe of the company. The news service cited two unnamed individuals as its sources for the article.
  • 07/27/2022

US opens criminal probe into pharma company over potential Alzheimer's drug fraud: report

  • A Texas-based pharmaceutical company is facing a criminal probe into allegations that it manipulated data in its studies on its Alzheimer's drug simuflam on Wednesday.
  • 07/27/2022

Cassava's stock dives 24% after report citing alleged criminal probe of data from Alzheimer's drug trial

  • Shares of Cassava Sciences Inc. SAVA, +0.14% plunged 24.2% in premarket trading on Wednesday after Reuters reported that the Justice Department is investigating whether the company manipulated clinical data for a still-investigational Alzheimer's disease drug, citing people familiar with the matter. Cassava put out a news release in December that said a scientific journal did not find evidence of manipulated data in a 2005 paper authored by the company's scientists after short sellers alleged data manipulation in some previously published research.
  • 07/27/2022

Exclusive-Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say

  • The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc involving whether the biotech company manipulated research results for its experimental Alzheimer's drug, two people familiar with the inquiry said.
  • 07/27/2022

7 Meme Stocks Trading at a Massive Discount Right Now

  • 'Meme mania' has long since passed, but there may be an opportunity with these seven meme stocks trading at a discount right now. The post 7 Meme Stocks Trading at a Massive Discount Right Now appeared first on InvestorPlace.
  • 07/24/2022

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

  • One probably should not invest in Cassava Sciences until all investigations are completed. Alternative mechanisms of action exist that better explain Cassava Sciences' trial results than the one offered by the company.
  • 06/10/2022

5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List

  • Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
  • 05/24/2022

Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms

  • Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point. The post Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms appeared first on InvestorPlace.
  • 04/29/2022

Take Full Advantage of Weakness in Cassava Sciences Stock

  • Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer's treatment, it could see $140 again.
  • 04/26/2022

Cassava Sciences Is a Worthwhile Bet to Consider

  • FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up. The post Cassava Sciences Is a Worthwhile Bet to Consider appeared first on InvestorPlace.
  • 04/25/2022

The Crowd Has Wisely Soured on Cassava Sciences Stock

  • As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock. The post The Crowd Has Wisely Soured on Cassava Sciences Stock appeared first on InvestorPlace.
  • 04/20/2022

Fresh Crop of Concerns Surrounding Alzheimer's Drug Sinks SAVA

  • The shares of Cassava Sciences Inc (NASDAQ:SAVA) are taking a drubbing this morning, last seen down 23.6% at $19.35, and set for their lowest open since January 2021.
  • 04/19/2022

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

  • Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufilam. Among the latest concerns highlighted in the NYT article include a report.
  • 04/19/2022

Why Is Cassava Sciences (SAVA) Stock Down Today?

  • SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory. The post Why Is Cassava Sciences (SAVA) Stock Down Today?
  • 04/19/2022

Cassava Sciences Is Worth Considering After Hitting Its Latest Trough

  • The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult.
  • 04/11/2022

3 Key Points To Remember About Cassava Sciences

  • Cassava Sciences is trading near its 52 week lows.
  • 04/07/2022

Why Is Cassava Sciences (SAVA) Stock Down Today?

  • Cassava Sciences (SAVA) stock is falling on Tuesday as investors react to a recent fireside chat held by CEO Remi Barbier. The post Why Is Cassava Sciences (SAVA) Stock Down Today?
  • 04/05/2022

Webcast Details for Cassava Sciences' Upcoming Fireside Chat

  • – All Stakeholder Are Welcome to Listen by Webcast –
  • 04/04/2022

Here's Why Cassava Sciences Stock Could Make a Comeback

  • It helps to have plenty of cold, hard cash.
  • 04/01/2022

Risk-on Biotech Investors Should Buy Cassava Sciences

  • SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer's drug nearing launch.
  • 03/30/2022

Keep Risk in Mind With Cassava Sciences Stock, but Don't Dismiss Upside Potential

  • If you can stomach the risk and have experience investing in clinical stage biotech plays, SAVA stock remains an interesting situation. After its recent weakness, you may find now to be the right time to initiate a position.
  • 03/15/2022

Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know

  • In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $37.31, marking a +0.54% move from the previous day.
  • 03/04/2022

Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days

  • SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time.
  • 03/03/2022

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

  • Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $42.51, moving +1.19% from the previous trading session.
  • 02/25/2022

Why Cassava Sciences Is Still a High-Risk Play

  • As it's not set in stone that Cassava Sciences will be able to bring simulfilam to market, you should approach SAVA stock cautiously. The post Why Cassava Sciences Is Still a High-Risk Play appeared first on InvestorPlace.
  • 02/25/2022

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

  • Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $49.22, moving +1.07% from the previous trading session.
  • 02/15/2022

The FDA Deals Another Blow To Cassava Sciences' Bears

  • The FDA Deals Another Blow To Cassava Sciences' Bears
  • 02/11/2022

Benzinga's Daily Brief On Trending Tickers For Feb. 11, 2022: Cassava Sciences, Cleveland Cliffs, GameStop, and More

  • Benzinga's “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks. The data on the trending tickers is compiled from a list of most-discussed tickers on the popular Reddit forum WallStreetBets.
  • 02/11/2022

Here is where you can Cassava Sciences stock (SAVA): it is up 7% today

  • After dropping since mid-November, the price of Cassava Sciences stock (SAVA) has bounced back and today it is up 7.78%. The current bullish outlook is a result of a denial by the FDA against Citizen Petitions Filed on Behalf of Short Selling Clients.
  • 02/11/2022

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

  • Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $47.12, moving +0.17% from the previous trading session.
  • 02/08/2022

Does Cassava Sciences and Its Alzheimer's Drug Really Have What It Takes?

  • Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows.
  • 02/08/2022

Keep an Eye on $60 as a Target Price for Cassava Sciences

  • As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time. The post Keep an Eye on $60 as a Target Price for Cassava Sciences appeared first on InvestorPlace.
  • 02/07/2022

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

  • Seeking Alpha longs have warned that increasing short positions in Cassava Sciences stock could result in a “short squeeze.”. For at least several days, comments on Seeking Alpha have disclosed that retail longs are receiving telephone calls from their brokers, asking if they are willing to loan their shares.
  • 02/02/2022

Are Herron Therapeutics, Cassava Sciences Ripe for a Short Squeeze?

  • As I pointed out in a previous discussion, short selling is not for the faint of heart and is probably best left to experienced traders. But there is an opportunity for investors to make money by keeping an eye on companies that could be subject to a short squeeze.
  • 01/25/2022

Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade

  • Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. The post Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade appeared first on InvestorPlace.
  • 01/24/2022

6 Top Biotech Ideas For 2022

  • 6 Top Biotech Ideas For 2022
  • 01/20/2022

Cassava Sciences Stock Is Still Risky but Has Plenty of Upside Potential

  • Still, weighing risk against potential gains, the odds with SAVA stock may be on your side. If you are active in similar types of plays, consider it one to put on your watchlist.
  • 01/18/2022

INmune Bio, The Biotech In My Stable For After Cassava Sciences

  • Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio's XPro to yield impressive results in its phase 2 trials like Cassava Sciences' simufilam did.
  • 01/17/2022

7 High Risk Stocks That Are Worth The Volatile Vibes

  • These seven high risk stocks made wild moves in 2021, but still have the potential to rocket higher. All are full of both risk and reward.
  • 01/10/2022

Where Will Cassava Sciences Be in 1 Year?

  • It could be a make-or-break year for the clinical-stage biotech.
  • 01/07/2022

Cassava Sciences, Inc. - The Short Squeeze Has Started

  • I provide and compare historical data from the GameStop and AMC short squeezes that occurred last year to Cassava Sciences. The short squeeze for Cassava Sciences has already started – as was the case for GameStop, recall that the increase in price-per-share for GameStop occurred over 12 trading days.
  • 01/06/2022

Cassava Sciences: Likelihood Of FDA Success Implies 11x Upside

  • The market is pricing in an approximately 6% chance of FDA approval for Cassava Sciences' Alzheimer's small molecule pill, Simufilam. The distribution of 147,000 Simufilam to more than 250 Alzheimer's patients in at least 16 investigator sites shows zero drug-related serious adverse events vs. 69% occurrence of ARIA with Biogen.
  • 01/03/2022

Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?

  • Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
  • 12/31/2021

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

  • I do not believe that a short position in Cassava Sciences stock is rational.
  • 12/30/2021

7 of the Best Meme Stocks for 2022 to Buy Now

  • Although the meme stocks phenomenon is sagging in popularity, these seven current and/or former Reddit favorites could make another "to the moon" move or two in 2022. The post 7 of the Best Meme Stocks for 2022 to Buy Now appeared first on InvestorPlace.
  • 12/30/2021

5 Stocks I'd Sell Right Now

  • These could be some of the worst-performing and riskiest investments in 2022.
  • 12/29/2021

Best Health Care Stocks To Buy Now? 3 For Your 2022 Watchlist

  • Health care stocks worth knowing as the Omicron Covid-19 variant sweeps the globe.
  • 12/28/2021

SAVA Stock Alert: What Is Going on With Red-Hot Cassava Sciences Today?

  • Biotech company Cassava saw a big jump today on positive news related to its Alzheimer's disease treatment. Keep an eye on SAVA stock.
  • 12/21/2021

Cassava Sciences Stock: Here We Go Again

  • While the interim data looks fantastic, and some are pushing for early approval of the drug by the FDA, some questions remain surrounding the academic integrity of the work.
  • 12/21/2021

Science Journal Finds No Evidence To Data Manipulation By Cassava Sciences' In 2005 Publication

  • Cassava Sciences Inc (NASDAQ: SAVA) has been informed by the Neuroscience journal that there is no evidence to support claims of data manipulation in a 2005 paper authored by the Company and its scientific collaborators.  "Another science journal has cleared us of allegations," said Remi Barbier, President & CEO.
  • 12/21/2021

Top Penny Stocks To Buy? 3 Former Stocks Under $5 To Watch Now

  • Are these former penny stocks on your list to buy right now or is the rally over? The post Top Penny Stocks To Buy?
  • 12/21/2021

SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today

  • Cassava Sciences (SAVA) stock is getting some extra attention today from traders on social media and we've got all the details. The post SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today appeared first on InvestorPlace.
  • 12/21/2021

Cassava Stock Surges as Social Media Buzz Intensifies

  • The shares of Cassava Sciences Inc (NASDAQ:SAVA) are surging before the bell, last seen up 33.6% at $49.13, as the heavily shorted stock gains popularity on social media this morning.
  • 12/21/2021

Cassava Sciences Stock (SAVA): Why The Price Surged

  • The shares of Cassava Sciences, Inc. (NASDAQ: SAVA) were halted this morning. This is why it happened.
  • 12/21/2021

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

  • These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.
  • 12/07/2021

Interview With Cassava Sciences' CEO Remi Barbier - Data Integrity, Elon Musk, And The Haters

  • We have a wide-ranging phone interview with Cassava Sciences' CEO Remi Barbier. He addresses crazy accusations and data safeguards.
  • 12/06/2021

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

  • Cassava Sciences has been one of 2021's best stocks. We can learn some things from Cassava to help us find the next great biotech or growth & innovation stock.
  • 12/01/2021

Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?

  • Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
  • 11/26/2021

Cassava Sciences Just Returned to the Buy Zone

  • There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. The post Cassava Sciences Just Returned to the Buy Zone appeared first on InvestorPlace.
  • 11/22/2021

Will Cassava Sciences Stock Continue To See Lower Levels?

  • The stock price of Cassava Sciences plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental Alzheimer's treatment - Simufilam. [1] SAVA stock saw a large fall in September following a citizen petition filed to.
  • 11/19/2021

Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam

  • Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease.  The second Phase 3 study is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks over 78 weeks in approximately 1,000 patients.
  • 11/18/2021

Is An Accelerated Approval Likely For Cassava Sciences?

  • Cassava Sciences is a company with a promising Alzheimer's Drug candidate. The FDA has a process called accelerated approval that allows for drugs to be approved for use before the finishing of drug trials.
  • 11/18/2021

Cassava (SAVA) Down on Report of SEC Investigation Into AD Program

  • Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
  • 11/18/2021

3 Biotech Stocks That Have More Than Tripled so far This Year

  • But can they keep up the momentum?
  • 11/18/2021

See Why Cassava Sciences Shares Are Falling On Wednesday?

  • The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer's drug simufilam. The report comes just two days after Cassava, in an SEC filing, revealed that “certain government agencies” had asked the Company for documentation.
  • 11/17/2021

Why Cassava Sciences Is Sliding Lower Today

  • Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten.
  • 11/17/2021

Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?

  • Today's hot penny stocks are catching the eyes of investors and we're diving into everything investors need to know about them on Wednesday! The post Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?
  • 11/17/2021

7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside

  • Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. The post 7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside appeared first on InvestorPlace.
  • 11/11/2021

Biogen Vs. Cassava Sciences Stock: Which Is The Better Buy?

  • Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for. BIIB's diversification, low sentiment, and profitability make it more suitable to a wider audience of investors.
  • 11/11/2021

Cassava Sciences: Cash Is King

  • The company's Q3 earnings "missed" expectations which is laughable. Cassava is increasing spending to get its phase 3 trials off the ground.
  • 11/10/2021

An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

  • An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
  • 11/10/2021

Cassava Sciences Stock: Top Contender For A Continued Short Squeeze

  • Cassava Sciences Stock: Top Contender For A Continued Short Squeeze
  • 11/10/2021

Cassava Sciences Needs Time and Data to Prove Itself Before You Buy

  • Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. The post Cassava Sciences Needs Time and Data to Prove Itself Before You Buy appeared first on InvestorPlace.
  • 11/09/2021

Cassava Is a Sell After Accusations of Data Manipulation

  • After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. The post Cassava Is a Sell After Accusations of Data Manipulation appeared first on InvestorPlace.
  • 11/09/2021

Cassava Sciences' Hypothesis Raises Doubts

  • Central to Cassava's hypothesis requires amyloid beta-42 to induce an altered conformation of structural protein filamin A and that sumifilam restores altered filmin A back to its native state. Researchers have demonstrated that mutations that cause familial AD, amyloid beta-40, and -42 production is more likely to be reduced or abolished due to decreased enzymatic activity of gamma-secretase.
  • 11/08/2021

4 Top Biotech Stocks To Watch This Week

  • Check out these biotech stocks that could prove to be valuable additions to your portfolio.
  • 11/08/2021

Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop

  • Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
  • 11/08/2021

Cassava Sciences: A Close Look

  • On Nov 4, Cassava Sciences issued a PR which headline reads, 'Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences' And the sub-heading: It states, "No evidence of data manipulation was found for Western blot data."
  • 11/06/2021

Stocks Heading Into Holiday Season With Record Highs

  • Stocks continued their run of near daily record highs heading into November, as investors digested a slew of economic updates and earnings reports.
  • 11/05/2021

Alzheimer's - Cassava Sciences, Cortexyme Or Anavex: Who Will Come On Top?

  • Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.
  • 11/05/2021

Cassava Sciences (SAVA) Stock: Why The Price Surged Today

  • The stock price of Cassava Sciences Inc (NASDAQ: SAVA) surged 48.96% today. This is why it happened.
  • 11/04/2021

Why Did Cassava Sciences Stock Jump 49% Today?

  • Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating Alzheimer's disease.  The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company's lead Alzheimer's candidate.
  • 11/04/2021

Cassava Sciences Stock Surges on Alzheimer's Article Update

  • Cassava Sciences Inc (NASDAQ:SAVA) is soaring today, up 46.1% to trade at $82.80 at last glance, after the company said the Journal of Neuroscience found no evidence of data manipulation in its 2012 article describing a new approach to treating Alzheimer's.
  • 11/04/2021

Cassava Sciences: Major Hit To The Bears

  • No evidence of data manipulation.
  • 11/04/2021

Why Cassava Sciences Shares Are Rising

  • Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company technical paper. "I've never doubted the integrity of our people or science," said Remi Barbier, President & CEO.
  • 11/04/2021

SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today

  • Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.
  • 11/04/2021

Is it too risky to buy Cassava Sciences as Quintessential says the stock is worthless?

  • On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares plunged more than 7% after Quintessential Capital management released a report saying the stock is worthless. The firm called for shorts to swoop in claiming its Alzheimer's drug Simufilam seems to be based on forged research.
  • 11/03/2021

Cassava Sciences Is on a Bumpy Road to Multibagger Status

  • Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds. The post Cassava Sciences Is on a Bumpy Road to Multibagger Status appeared first on InvestorPlace.
  • 11/03/2021

Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?

  • Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
  • 11/01/2021

Cassava Sciences Stock: Massive Potential Marred By Controversy

  • Cassava Sciences, Inc. is a pre-revenue biotechnology company. The company specializes in neurodegenerative diseases, such as Alzheimer's disease.
  • 11/01/2021

Cassava Sciences' Stock Remains an Enigma

  • Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run.
  • 11/01/2021

Buy SAVA Stock on Dips as its Phase 3 Trial Moves Along

  • There's no way to mitigate its high risk nature completely. But if you're bullish on Simulfilam?
  • 10/29/2021

Cassava Sciences: Welcome To The Casino

  • There is a lot of hope with this one for those suffering from Alzheimer's.
  • 10/25/2021

3 Biotech Stocks That Are Ridiculously Overpriced

  • They've risen too far, too quickly.
  • 10/20/2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)

  • New York, New York--(Newsfile Corp. - October 19, 2021) -  The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20539&from=5
  • 10/19/2021

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • New York, New York--(Newsfile Corp. - October 19, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20530&wire=5
  • 10/19/2021

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

  • New York, New York--(Newsfile Corp. - October 19, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20524&from=5
  • 10/19/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA

  • New York, New York--(Newsfile Corp. - October 18, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that...
  • 10/18/2021

SHAREHOLDER ALERT: SAVA WDH HNST: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • NEW YORK, NY / ACCESSWIRE / October 18, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
  • 10/18/2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA

  • New York, New York--(Newsfile Corp. - October 18, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
  • 10/18/2021

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPLT, SAVA and SPPI

  • NEW YORK, NY / ACCESSWIRE / October 17, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
  • 10/17/2021

Rosen, Top Ranked Investor Counsel, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA

  • New York, New York--(Newsfile Corp. - October 16, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of...
  • 10/16/2021

Cassava Update

  • Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 16, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal...
  • 10/16/2021

(SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Cassava Class Action Lawsuit

  • SAN DIEGO, Oct. 16, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). The class action is on behalf of shareholders who purchased Generac common stock between September 14, 2020 and August 27, 2021.
  • 10/16/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA

  • NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers.  The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period").
  • 10/15/2021
Unlock
SAVA Ratings Summary
SAVA Quant Ranking